Adam Friedman

Life sciences entrepreneur, physician, scientist @ Antares Therapeutics.

[Antares Therapeutics @antares_rx]

We’re at #ASCO this week where the latest breakthroughs in cancer research come together. We're looking forward to a great meeting connecting with colleagues across the industry and discussing the latest advances in cancer research.
#ASCO26 #PrecisionOncology #CancerResearch

[Antares Therapeutics @antares_rx]

We’re thrilled to share that Antares has been nominated for a #NEVYs25 Emerging Company of the Year Award in Therapeutics! Thank you to @NewEnglandVC for recognizing our commitment to transforming patient lives through pioneering precision medicines.
Learn more about the NEVYs: https://t.co/jjesMkEk2T
#NEVCA #Innovation

[Adam Friedman @othersbringdata]

Today marks the launch of Antares Therapeutics, spinout of Scorpion Tx, following its acquisition earlier this year. I am grateful to the entire Antares team for their ingenuity & dedication to patients as we continue our mission to bring transformative medicines to patients.

[Antares Therapeutics @antares_rx]

🚀Exciting news! Antares Therapeutics launches with $177M Series A funding to develop transformational, first-in-class precision medicines for cancer & other serious diseases. Led by an expert team, we're advancing innovation to meet unmet needs. Learn more at https://t.co/hmeBQKQkrd!

[Bruce Booth @LifeSciVC]

Congrats to the drug hunters at @ScorpionTx for the sale of their PI3K program to $LLY!
Compelling clinical data is the coin of the realm. Kudos to @othersbringdata and the rest of the team!

https://t.co/LGI0BsOUmG

Excited to see "Chapter 2" unfold with the new spinout!

[Bruce Booth @LifeSciVC]

The Scorpion Therapeutics story is a great one for many reasons, but it’s a fantastic story about long term relationships and the importance of patient people-centric investing.

CEO Adam Friedman joined Atlas over 15 years ago in 2010 as an EIR, working across several Atlas companies for the next six years. Co-founder Gary Glick had just exited IFM with us when Scorpion came together. Board Director Saurabh Saha was also previously an Atlas CEO at Delinia. Jeff Albers, exec chair of Scorpion, is an Atlas Venture Partner we’ve known for years. Our partner Jean Francois Formela seeded it and helped bring all these people and pieces together - including a great group of co-investors over time.

And this deep connectivity matters. Lilly’s Dan Skovronsky got a chance to get to know Adam well at last fall’s Atlas Venture Retreat… helping lead to a productive deal process around STX-478.

Talented entrepreneurs and executives - both drug hunters and deal-makers - are what make this ecosystem thrive. Kudos to all of them involved.

@othersbringdata @JFFormela @OtelloVC

[Lei Lei Wu @leilei_wuu]

Scorpion raises $150M with sights on the next wave of targeted therapies

https://t.co/Vmr8acier5

[FierceBiotech @FierceBiotech]

As it broadens the clinical ambitions for its small molecule oncology programs, Scorpion Therapeutics has secured $150 million in financial fuel. https://t.co/k8txD2sPma

[Vida Ventures @Vida_Ventures]

@ScorpionTx announced the closing of their $150 Million Series C financing, advancing their growing precision oncology pipeline and redefining the outcomes for people living with cancer. Congratulations, Scorpion! Learn more: https://t.co/BWA0BrWbCD #VidaPortfolio

[Adam Friedman @othersbringdata]

We’ve disclosed three of these clinical candidates so far & look forward to disclosing more in the coming months & years. I’m proud of the incredible work by all the Scorpions & look forward to what the next few years will bring to the company and to patients with cancer. (10/10)

[Adam Friedman @othersbringdata]

Today, @ScorpionTx announced the close of its Series C financing. Financings are a means to an end – delivering transformational medicines to patients, but I’d like to take a moment to give some more detail on what this means and why this is important for Scorpion: (1/10)

[Adam Friedman @othersbringdata]

(2) a mechanism-agnostic approach to tackling those targets, whether covalent, non-covalent, allosteric, degrader, glue, etc., integrating computational & experimental technologies. Our goal is to create truly best-in-class medicines, using whatever tool it takes. (9/10)

[Cell @CellCellPress]

Now online! DrugMap: A quantitative pan-cancer analysis of cysteine ligandability https://t.co/SElGVOUOAp

[Adam Friedman @othersbringdata]

Congratulations to @ScorpionTx scientific founder and collaborator, @LironBarPeled on the publication of this important milestone in chemical proteomics and cancer.

[Liron Bar-Peled @LironBarPeled]

Today is a special day. Our multi-year study led by an AMAZING group of scientists @MarikoTakahas17, Harrison Chong and Siwen Zhang comes out @CellCellPress. DrugMap: A quantitative pan-cancer analysis of cysteine ligandability. Check it out here: https://t.co/OgCisVxeye.